menu
    • menu
    [{"orgOrder":0,"company":"Escape Bio","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"ESB1609","moa":"S1P5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Escape Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escape Bio \/ Wellington Management Company","highestDevelopmentStatusID":"6","companyTruncated":"Escape Bio \/ Wellington Management Company"},{"orgOrder":0,"company":"Escape Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ESB1609","moa":"S1P5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Escape Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escape Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Escape Bio \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Escape Bio

    Menu

    Escape Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Escape Bio

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed

                            Escape Bio

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ESB1609

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : Wellington Management Company

                            Deal Size : $73.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Escape Bio Closes $73 Million to Advance Clinical Development of Precision Neurology Medicines for Genetic Neu...

                            Details : ESCAPE Bio is developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases. ESB1609 is in a Phase 1 multiple ascending dose study in healthy volunteers.

                            Product Name : ESB1609

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 14, 2020

                            Lead Product(s) : ESB1609

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : Wellington Management Company

                            Deal Size : $73.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Escape Bio

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed

                            Escape Bio

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ESB1609

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ESCAPE Bio Announces Excellent Safety and Tolerability in Phase 1 Study of Oral S1P5 Receptor Agonist ESB1609

                            Details : ESB1609 demonstrated durable CSF pharmacokinetics and excellent safety & tolerability in a single ascending dose Phase 1 Study.

                            Product Name : ESB1609

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 01, 2020

                            Lead Product(s) : ESB1609

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth